U.S. will again offer free at-home Covid tests starting in late September

U.S. will again offer free at-home Covid tests starting in late September


Images By Tang Ming Tung | DigitalVision | Getty Images

The Biden administration on Friday said it will resume offering free at-home Covid-19 tests to American households in late September as the virus has gained a stronger foothold in the U.S. this summer.

Americans will soon be able to use COVIDtests.gov to request four free tests, administration officials told reporters during a briefing. The tests will be able to detect the Covid variants that are currently circulating, most of which are descendants of the highly contagious omicron variant JN.1. 

“These tests will help keep families and their loved ones safe this fall and winter season,” Dawn O’Connell, an assistant secretary for preparedness and response at the Health and Human Services Department, said during the briefing. “This is the seventh time over the last three years that the Biden-Harris administration has given families the opportunity to order the over-the-counter Covid-19 tests for free” through the government’s website.

The government’s program has provided more than 1.8 billion free over-the-counter Covid tests to Americans since it started in 2021, according to O’Connell.

The government is relaunching the program amid a relatively large spike in Covid cases this summer, and ahead of the fall and winter, when the virus typically spreads at higher levels each year. There is a “high” or “very high” level of Covid being detected in wastewater in almost every U.S. state, according to data from the Centers for Disease Control and Prevention. 

But the government decided to reopen the program in late September because it’s when more Americans begin to travel and gather indoors with loved ones. 

More CNBC health coverage

“As people start to travel, as they start to get together with friends and family through the holidays, we want them to have those four tests available to them at that time,” David Boucher, director of infectious disease preparedness and response at HHS, told reporters during the briefing.

By then, the latest round of Covid shots from Pfizer and Moderna will be available to most Americans in pharmacies, health clinics and other locations nationwide. The Food and Drug Administration approved those shots, which target a JN.1 offshoot called KP.2, on Thursday.

Testing is a critical tool for protection as Covid infections climb again. But lab PCR tests — the traditional method of detecting Covid — have become more expensive and less accessible for some Americans since the U.S. government ended the public health emergency in May last year. 

Still, certain local health clinics and community sites offer at-home tests to the public at no cost. 

Don’t miss these insights from CNBC PRO



Source

First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. 
Health

First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. 

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Nov. 24, 2025. Tom Little | Reuters Novo Nordisk will start rolling out the first-ever GLP-1 pill for weight loss in the U.S. on Monday, the company announced, marking a new chapter of obesity […]

Read More
2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit
Health

2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit

The ripple is about to become a wave. Right now, there are numerous barriers for people who are considering treating their obesity with GLP-1 drugs. Early on, there were manufacturing bottlenecks that resulted in short supplies of Novo Nordisk ‘s Wegovy and Eli Lilly ‘s Zepbound. There were insurance coverage issues for these pricey treatments, […]

Read More
Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Health

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of […]

Read More